Trillium Therapeutics Inc.Find Ratings Reports
TRILLIUM THERAPEUTICS INC's gross profit margin for the second quarter of its fiscal year 2021 has significantly decreased when compared to the same period a year ago. Even though sales decreased, the net income has increased. TRILLIUM THERAPEUTICS INC is extremely liquid. Currently, the Quick Ratio is 19.43 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 117.34% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY21||Q2 FY20|
|Net Sales ($mil)||0.01||0.12|
|Net Income ($mil)||-18.4||-23.22|
|Balance Sheet||Q2 FY21||Q2 FY20|
|Cash & Equiv. ($mil)||264.54||130.83|
|Total Assets ($mil)||273.68||136.15|
|Total Debt ($mil)||0.73||0.91|
|Profitability||Q2 FY21||Q2 FY20|
|Gross Profit Margin||-186130.0||-20527.83|
|Return on Assets||-17.93||-52.33|
|Return on Equity||-18.91||-59.66|
|Debt||Q2 FY21||Q2 FY20|
|Share Data||Q2 FY21||Q2 FY20|
|Shares outstanding (mil)||104.77||84.58|
|Div / share||0.0||0.0|
|Book value / share||2.48||1.41|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||2751636.0||1411476.0|
HOLD. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 7.21 indicates a significant premium versus the S&P 500 average of 4.43 and a significant discount versus the subsector average of 10.43. The price-to-sales ratio is well above both the S&P 500 average and the subsector average, indicating a premium. The valuation analysis reveals that, TRILLIUM THERAPEUTICS INC seems to be trading at a premium to investment alternatives.
|TRIL NM||Peers 31.52||TRIL NM||Peers 19.38|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
TRIL's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
TRIL's P/CF is negative making the measure meaningless.
|TRIL NA||Peers 17.23||TRIL NA||Peers 0.35|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|TRIL 7.21||Peers 10.43||TRIL 69.52||Peers 236.90|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
TRIL is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, TRIL is expected to significantly trail its peers on the basis of its earnings growth rate.
|TRIL 46805.10||Peers 1442.02||TRIL -82.45||Peers 1994.96|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
TRIL is trading at a significant premium to its subsector.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
TRIL significantly trails its peers on the basis of sales growth.